Alzheimer's & dementia (New York, N. Y.)
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
Communicating Alzheimer's biomarker results to cognitively unimpaired research participants: Satisfaction, utility, and impact on research attitudes..
10:-.
2024
-
post mortem.
10:-.
2024
-
The importance of the dyad: Participant perspectives on sharing biomarker results in Alzheimer's disease research..
9:-.
2023
-
Effects of methylphenidate on neuropsychiatric symptoms in Alzheimer's disease: Evidence from the ADMET 2 study..
9:-.
2023
-
Feasibility of virtual Alzheimer's biomarker disclosure: Findings from an observational cohort..
9:-.
2023
-
Meaningful benefit and minimal clinically important difference (MCID) in Alzheimer's disease: Open peer commentary..
9:-.
2023
-
Barriers and facilitators to participating in Alzheimer's disease biomarker research in black and white older adults..
9:-.
2023
-
Accelerating diversity in Alzheimer's disease research by partnering with a community advisory board..
9:-.
2023
-
A boot camp translation of Alzheimer's disease in Hispanic/Latino communities..
9:-.
2023
-
Listening session with the US Food and Drug Administration, Lewy Body Dementia Association, and an expert panel..
9:-.
2023
-
The Alzheimer's Cell Atlas (TACA): A single-cell molecular map for translational therapeutics accelerator in Alzheimer's disease..
8:-.
2022
-
Emergency department care transition barriers: A qualitative study of care partners of older adults with cognitive impairment..
8:-.
2022
-
Chronic neuropsychiatric sequelae of SARS-CoV-2: Protocol and methods from the Alzheimer's Association Global Consortium..
8:-.
2022
-
Measures of religion and spirituality in dementia: An integrative review..
8:-.
2022
-
Alzheimer's polygenic hazard score in SuperAgers: SuperGenes or SuperResilience?.
8:-.
2022
-
Home health utilization association with discharge to community for people with dementia..
8:-.
2022
-
Effect of masupirdine (SUVN-502) on cognition in patients with moderate Alzheimer's disease: A randomized, double-blind, phase 2, proof-of-concept study..
8:-.
2022
-
Alzheimer's disease drug development pipeline: 2022..
8:-.
2022
-
Proportional constrained longitudinal data analysis models for clinical trials in sporadic Alzheimer's disease..
8:-.
2022
-
Impact of non-binding FDA guidances on primary endpoint selection in Alzheimer's disease trials..
8:-.
2022
-
Virtual reality cognitive intervention for heart failure: CORE study protocol..
8:-.
2022
-
Barriers to seeking care for memory problems: A vignette study..
8:-.
2022
-
Care transitions intervention reduces ED revisits in cognitively impaired patients..
8:-.
2022
-
Reproducibility and replicability of high-frequency, in-home digital biomarkers in reducing sample sizes for clinical trials..
7:-.
2021
-
Dementia risk reduction: why haven't the pharmacological risk reduction trials worked? An in-depth exploration of seven established risk factors..
7:-.
2021
-
Subjective cognitive decline higher among sexual and gender minorities in the United States, 2015-2018..
7:-.
2021
-
Who funds Alzheimer's disease drug development?.
7:-.
2021
-
Practices, challenges, and opportunities when addressing the palliative care needs of people living with dementia: Specialty memory care provider perspectives..
7:-.
2021
-
The Cognitive & Leisure Activity Scale (CLAS): A new measure to quantify cognitive activities in older adults with and without cognitive impairment..
7:-.
2021
-
Predicting amyloid risk by machine learning algorithms based on the A4 screen data: Application to the Japanese Trial-Ready Cohort study..
7:-.
2021
-
Factors influencing transition to care homes for people with dementia in Northern Ireland..
7:-.
2021
-
Association of the use of hearing aids with the conversion from mild cognitive impairment to dementia and progression of dementia: A longitudinal retrospective study..
7:-.
2021
-
Effects of physical activities on dementia-related biomarkers: A systematic review of randomized controlled trials..
6:-.
2021
-
Association of CSF Alzheimer's disease biomarkers with postoperative delirium in older adults..
7:-.
2021
-
Choosing the right time granularity for analysis of digital biomarker trajectories..
6:-.
2020
-
Evaluating the Alzheimer's disease data landscape..
6:-.
2020
-
Targeting abnormal metabolism in Alzheimer's disease: The Drug Repurposing for Effective Alzheimer's Medicines (DREAM) study..
6:-.
2020
-
Differentiating among stages of cognitive impairment in aging: Version 3 of the Uniform Data Set (UDS) neuropsychological test battery and MoCA index scores..
6:-.
2020
-
Agitation and impulsivity in mid and late life as possible risk markers for incident dementia..
6:-.
2020
-
Approximating dementia prevalence in population-based surveys of aging worldwide: An unsupervised machine learning approach..
6:-.
2020
-
Sensing a problem: Proof of concept for characterizing and predicting agitation..
6:-.
2020
-
Using care navigation to address caregiver burden in dementia: A qualitative case study analysis..
6:-.
2020
-
Effectiveness of online education for recruitment to an Alzheimer's disease prevention clinical trial..
6:-.
2020
-
The Area Deprivation Index: A novel tool for harmonizable risk assessment in Alzheimer's disease research..
6:-.
2020
-
A blood-based nutritional risk index explains cognitive enhancement and decline in the multidomain Alzheimer prevention trial..
953-963.
2019
-
Associations of hemoglobin A1c with cognition reduced for long diabetes duration..
926-932.
2019
-
Telomere length associations with cognition depend on Alzheimer's disease biomarkers..
883-890.
2019
-
Recruitment and retention of underrepresented populations in Alzheimer's disease research: A systematic review..
751-770.
2019
-
The cross-sectional association of cognitive stimulation factors and cognitive function among Latino adults in Hispanic Community Health Study/Study of Latinos (HCHS/SOL)..
533-541.
2019
-
Two-period linear mixed effects models to analyze clinical trials with run-in data when the primary outcome is continuous: Applications to Alzheimer's disease..
450-457.
2019
-
Differential effects of neurodegeneration biomarkers on subclinical cognitive decline..
129-138.
2019
-
Simultaneously evaluating the effect of baseline levels and longitudinal changes in disease biomarkers on cognition in dominantly inherited Alzheimer's disease..
669-676.
2018
-
Amyloid-associated increases in longitudinal report of subjective cognitive complaints..
444-449.
2018
-
Current understanding of magnetic resonance imaging biomarkers and memory in Alzheimer's disease..
395-413.
2018
-
Neuroimaging and neuropsychological assessment of freezing of gait in Parkinson's disease..
387-394.
2018
-
Translational inhibition of APP by Posiphen: Efficacy, pharmacodynamics, and pharmacokinetics in the APP/PS1 mouse..
37-45.
2018
-
Longitudinal patterns of potentially inappropriate medication use following incident dementia diagnosis..
1-10.
2017
-
Integrating sex and gender into neurodegeneration research: A six-component strategy..
3:660-667.
2017
-
Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: The PACC5..
3:668-677.
2017
-
Serum concentrations of vitamin E and carotenoids are altered in Alzheimer's disease: A case-control study..
3:432-439.
2017
-
A Dopamine Receptor genetic variant enhances perceptual speed in cognitive healthy subjects..
3:254-261.
2017
-
Impact of programs to reduce antipsychotic and anticholinergic use in nursing homes..
3:553-561.
2017
-
Predicting mild cognitive impairment from spontaneous spoken utterances..
3:219-228.
2017
-
Bladder antimuscarinics and cognitive decline in elderly patients..
3:139-148.
2017
-
Preclinical Alzheimer's disease and longitudinal driving decline..
3:74-82.
2017
-
Communication Bridge: A pilot feasibility study of Internet-based speech-language therapy for individuals with progressive aphasia..
2:213-221.
2016
-
Proof of concept demonstration of optimal composite MRI endpoints for clinical trials..
2:177-181.
2016
-
Considerations for the assessment of suicidal ideation and behavior in older adults with cognitive decline and dementia..
2:48-59.
2016
-
Suicidal ideation and behavior assessment in dementia studies: An Internet survey..
2:60-68.
2016
-
Is late-onset Alzheimer's disease really a disease of midlife?.
1:122-130.
2015
Identity
International Standard Serial Number (ISSN)